Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 48Lung Neoplasms 24Carcinoma, Hepatocellular 24Small Cell Lung Carcinoma 16Urinary Bladder Neoplasms 12Cholangiocarcinoma 12Breast Neoplasms 10Liver Neoplasms 9Biliary Tract Neoplasms 9Neoplasms 8Neoplasm Metastasis 8Pancreatic Neoplasms 7Carcinoma 6Endometrial Neoplasms 5Colorectal Neoplasms 5Triple Negative Breast Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Gallbladder Neoplasms 4Carcinoma, Transitional Cell 4Ovarian Neoplasms 3Neoplasms by Site 3Carcinoma, Renal Cell 3Bile Duct Neoplasms 3Adenocarcinoma 3Thyroid Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Respiratory Tract Neoplasms 2Pathologic Complete Response 2

Interventions

pembrolizumab 53Paclitaxel 20Cisplatin 15Carboplatin 15lenvatinib 10Docetaxel 9Saline Solution 7Capecitabine 7Pemetrexed 6Oxaliplatin 6Gemcitabine 6Fluorouracil 6Leucovorin 5Albumin-Bound Paclitaxel 5olaparib 4belzutifan 4Bevacizumab 4130-nm albumin-bound paclitaxel 4patritumab deruxtecan 3Glucose 3Acetaminophen 3liposomal doxorubicin 2Levoleucovorin 2Irinotecan 2Histamine H2 Antagonists 2Histamine Antagonists 2Etoposide 2Doxorubicin 2Dexamethasone 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × durvalumab × 90 days × Clear all
NCT04380636 2026-05-15

MK-7339-012

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
870 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡